LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021
Print article
Image: LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021 (Photo courtesy of LumiQuick Diagnostics, Inc.)
Image: LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021 (Photo courtesy of LumiQuick Diagnostics, Inc.)

LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) highlighted its newly-launched point-of-care lateral flow assays and ELISA kits at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The event provided an opportunity to connect with global leaders in laboratory medicine, and to discover cutting edge technology and vital research in the field. LumiQuick develops and manufactures extensive product lines that cover point-of-care lateral flow assays, ELISA kits, and other platforms. At AACC 2021, the company highlighted some of its newly-launched products such as the QuickProfile Quantitative Vitamin D rapid test, QuickProfile Zika IgG/IgM antibody rapid test, QuickProfile Chikungunya IgG/IgM antibody rapid test, and Quicknostics Vitamin D ELISA test.

LumiQuick also demonstrated its COVID-19 testing solutions including the QuickProfile 2019-nCoV IgG/IgM Combo Test Card which is an immunochromatography based one step in vitro test. It is designed for the rapid qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV, SARS-CoV-2) in human serum, plasma, or whole blood. Rapid 2019-nCoV IgG/IgM Combo Test Card is a supplemental rapid screening tool for symptomatic or asymptomatic carriers of the virus. Also on display was the company’s QuickProfile COVID-19 Antigen Test which is a rapid in vitro immunochromatographic assay for the qualitative detection of SARS-CoV-2 virus antigen present in human nasopharynx.

Related Links:
LumiQuick Diagnostics, Inc. 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.